Low-dose GH improves exercise capacity in adults with GH deficiency: effects of a 22-month placebo-controlled, crossover trial

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Low-dose GH improves exercise capacity in adults with GH deficiency: effects of a 22-month placebo-controlled, crossover trial. / Bollerslev, J; Hallen, J; Fougner, KJ; Jorgensen, AP; Kristo, C; Fagertun, H; Gudmundsen, O; Burman, Pia; Schreiner, T.

I: European Journal of Endocrinology, Vol. 153, Nr. 3, 2005, s. 379-387.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Bollerslev, J, Hallen, J, Fougner, KJ, Jorgensen, AP, Kristo, C, Fagertun, H, Gudmundsen, O, Burman, P & Schreiner, T 2005, 'Low-dose GH improves exercise capacity in adults with GH deficiency: effects of a 22-month placebo-controlled, crossover trial', European Journal of Endocrinology, vol. 153, nr. 3, s. 379-387. https://doi.org/10.1530/eje.1.01971

APA

Bollerslev, J., Hallen, J., Fougner, KJ., Jorgensen, AP., Kristo, C., Fagertun, H., ... Schreiner, T. (2005). Low-dose GH improves exercise capacity in adults with GH deficiency: effects of a 22-month placebo-controlled, crossover trial. European Journal of Endocrinology, 153(3), 379-387. https://doi.org/10.1530/eje.1.01971

CBE

MLA

Vancouver

Author

Bollerslev, J ; Hallen, J ; Fougner, KJ ; Jorgensen, AP ; Kristo, C ; Fagertun, H ; Gudmundsen, O ; Burman, Pia ; Schreiner, T. / Low-dose GH improves exercise capacity in adults with GH deficiency: effects of a 22-month placebo-controlled, crossover trial. I: European Journal of Endocrinology. 2005 ; Vol. 153, Nr. 3. s. 379-387.

RIS

TY - JOUR

T1 - Low-dose GH improves exercise capacity in adults with GH deficiency: effects of a 22-month placebo-controlled, crossover trial

AU - Bollerslev, J

AU - Hallen, J

AU - Fougner, KJ

AU - Jorgensen, AP

AU - Kristo, C

AU - Fagertun, H

AU - Gudmundsen, O

AU - Burman, Pia

AU - Schreiner, T

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pediatrics/Urology/Gynecology/Endocrinology (013240400), Diabetes and Endocrinology (013241530)

PY - 2005

Y1 - 2005

N2 - Fifty-five patients with adult-onset GH deficiency (mean age, 49 years) were enrolled in a placebo-controlled, crossover study to investigate the effects of GH therapy on exercise capacity, body composition, and quality of life QOL). GH and placebo were administered for 9 months each, separated, by a 4-month washout period. GH therapy was individually dosed to obtain an IGF-I concentration within the normal range for age and sex. The final mean daily dose of GH was 1.2 IU/day for men and 1.8 IU/day for women. Mean lGF-I concentration at baseline was higher in men than in women(9 95 +/- 33 vs 68 +/- 41 mu g/l respectively; P < 0.04) and increased to a similar level on GH therapy. Body fat mass was reduced by 1.9 +/- 2.9 kg and lean body mass was increased by 1.8 +/- 2.8 kg (P = 0.0001 for each) with GH treatment. Total and low-density cholesterol levels decreased. Absolute maximal oxygen uptake increased by 6% (P = 0.01), relative to body weight by 9% (P = 0.004), and there was a trend toward increased endurance performance by 7% (P = 0.07). There were no significant effects on QOL. In conclusion, treatment with a low, physiologic dose of GH produced positive effects on body composition and lipids and improved exercise capacity, likely to be of clinical relevance. No changes in QOL were seen, possibly because of a good QOL at baseline.

AB - Fifty-five patients with adult-onset GH deficiency (mean age, 49 years) were enrolled in a placebo-controlled, crossover study to investigate the effects of GH therapy on exercise capacity, body composition, and quality of life QOL). GH and placebo were administered for 9 months each, separated, by a 4-month washout period. GH therapy was individually dosed to obtain an IGF-I concentration within the normal range for age and sex. The final mean daily dose of GH was 1.2 IU/day for men and 1.8 IU/day for women. Mean lGF-I concentration at baseline was higher in men than in women(9 95 +/- 33 vs 68 +/- 41 mu g/l respectively; P < 0.04) and increased to a similar level on GH therapy. Body fat mass was reduced by 1.9 +/- 2.9 kg and lean body mass was increased by 1.8 +/- 2.8 kg (P = 0.0001 for each) with GH treatment. Total and low-density cholesterol levels decreased. Absolute maximal oxygen uptake increased by 6% (P = 0.01), relative to body weight by 9% (P = 0.004), and there was a trend toward increased endurance performance by 7% (P = 0.07). There were no significant effects on QOL. In conclusion, treatment with a low, physiologic dose of GH produced positive effects on body composition and lipids and improved exercise capacity, likely to be of clinical relevance. No changes in QOL were seen, possibly because of a good QOL at baseline.

U2 - 10.1530/eje.1.01971

DO - 10.1530/eje.1.01971

M3 - Article

VL - 153

SP - 379

EP - 387

JO - European Journal of Endocrinology

T2 - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 1479-683X

IS - 3

ER -